Harvard Management Company Invests in New Biopharmaceutical Companies, Including COVID-19 Vaccine Hopeful | News | The Harvard Crimson

The Harvard Management Company added three biopharmaceutical companies — including a firm developing a coronavirus vaccine candidate — to its investment portfolio in the second quarter as the overall value of their public securities holdings dropped 28 percent.

Read the full article here

Related Articles